Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
出版年份 2020 全文链接
标题
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
作者
关键词
-
出版物
ADVANCES IN THERAPY
Volume 37, Issue 6, Pages 2678-2695
出版商
Springer Science and Business Media LLC
发表日期
2020-05-18
DOI
10.1007/s12325-020-01378-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparative efficacy of second-line treatments for advanced hepatocellular carcinoma: A network meta-analysis.
- (2020) Neehar Parikh et al. JOURNAL OF CLINICAL ONCOLOGY
- Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
- (2019) Simon Chowdhury et al. ADVANCES IN THERAPY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis
- (2018) Elvira Schmidt et al. Targeted Oncology
- Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
- (2018) Gabriel Tremblay et al. Cancer Management and Research
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Second-line Treatments of Advanced Hepatocellular Carcinoma
- (2018) Ziad Bakouny et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA
- (2018) N. Roskell et al. VALUE IN HEALTH
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC): Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib
- (2017) M Venkatachalam et al. VALUE IN HEALTH
- TAM receptor tyrosine kinase function and the immunopathology of liver disease
- (2016) S. K. Mukherjee et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Matching Adjusted Indirect Comparisons To Assess Comparative Effectiveness Of Therapies: Usage In Scientific Literature And Health Technology Appraisals
- (2016) H Thom et al. VALUE IN HEALTH
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Evaluating the Quality of Evidence from a Network Meta-Analysis
- (2014) Georgia Salanti et al. PLoS One
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started